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a b s t r a c t
Neural precursor cells (NPCs) are the subject of intense investigation for their potential to treat
neurodegenerative disorders, yet the consequences of neuroinvasive virus infection of NPCs remain
unclear. This study demonstrates that NPCs support replication following infection by the neurotropic
JHM strain of mouse hepatitis virus (JHMV). JHMV infection leads to increased cell death and dampens
IFN-γ-induced MHC class II expression. Importantly, cytokines secreted by CD4þ T cells inhibit JHMV
replication in NPCs, and CD8þ T cells speciﬁcally target viral peptide-pulsed NPCs for lysis. Furthermore,
treatment with IFN-γ inhibits JHMV replication in a dose-dependent manner. Together, these ﬁndings
suggest that T cells play a critical role in controlling replication of a neurotropic virus in NPCs, a ﬁnding
which has important implications when considering immune modulation for NPC-based therapies for
treatment of human neurologic diseases.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Transplantation of multipotent neural precursor cells (NPCs) is
emerging as a feasible therapeutic strategy for the treatment of a
variety of neurological disorders. Recent studies have demonstrated
both short and long-term clinical beneﬁts following NPC engraftment
within the context of rodent models of Alzheimer's disease, Parkin-
son's disease, Huntington's disease, and acute spinal cord injury
(Blurton-Jones et al., 2009; McBride et al., 2004; van Gorp et al.,
2013; Yasuhara et al., 2006). Furthermore, in murine and non-human
primate models of the neuroinﬂammatory disease multiple sclerosis
(MS) the ability of human NPCs to function as modulators of the
immune system in addition to replacing lost or damaged neural cell
populations has been suggested (Aharonowiz et al., 2008; Pluchino
et al., 2003, 2009). However, despite the clinical and histological
beneﬁts of NPC transplantation in pre-clinical animal models of
neurologic disease, there is limited evidence addressing the capacity
of neural grafts to act as reservoirs for viral replication. Studies using
the non-polio enterovirus coxsackievirus B (CVB) demonstrate the
ability of CVB to preferentially replicate in murine NPCs (Ruller et al.,
2012). The ensuing carrier-state infection results in increased cell
death and impaired differentiation potential in vitro, as well as
inﬂammation, microgliosis, and a variety of CNS developmental
defects in vivo (Ruller et al., 2012; Tsueng et al., 2011). Intracerebral
infection of neonates with murine cytomegalovirus (MCMV) results
in the loss of neural stem cells and their neuronal progeny, as well as
a decrease in the production of neurotrophins imperative to normal
brain development (Mutnal et al., 2011). Borna disease virus (BDV)
infection of human fetal human NPCs results in cell death upon
differentiation and impaired neurogenesis (Brnic et al., 2012). Thus,
the role of neural stem and progenitors as targets for a variety of
neuroinvasive viruses is evident, while the consequences of infection
within the context of cellular therapy remain to be elucidated.
Complicating NPC-based therapies is the controversial issue of
antigenicity of transplanted cells and immune-mediated recogni-
tion. A growing body of evidence suggests NPCs are not immuno-
privileged, as has previously been reported (Hori et al., 2003).
Indeed, we have shown that NPCs derived from post-natal C57BL/6
brains express the co-stimulatory molecules CD80 and CD86 and
up-regulate major histocompatibility complex (MHC) molecules in
response to the pro-inﬂammatory cytokine interferon gamma
(IFN-γ) (Weinger et al., 2012). Furthermore, allogeneic NPCs are
rapidly rejected via a T cell mediated mechanism following
intraspinal transplantation into MHC-mismatched recipients
(Weinger et al., 2012). Similarly, human NPCs have the capacity
to express MHCs I and II and induce T cell proliferation (Goya et al.,
2011). The apparent antigenicity of NPCs suggests successful
engraftment may require the use of immunomodulatory agents
and lifelong suppression of the immune system, as with solid
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organ transplants. However, an unintended consequence of immune
suppression is the potential for latent viruses to become activated, or
for uncontrolled viral replication to occur following opportunistic
infection (Crough et al., 2007; Jordan et al., 1977; Wynn et al., 2010;
Young et al., 2012). Therefore, it is imperative to understand the
consequences of neurotropic virus infection of NPCs as cell-
replacement therapies continue to move into the clinic (Gupta et al.,
2012; Riley et al., 2013).
In this study, we demonstrate that cultured murine NPCs are
infected by the neurotropic JHM strain of mouse hepatitis virus
(JHMV), which induces acute encephalomyelitis and chronic
demyelination when injected intracranially into immunocompe-
tent mice. JHMV-infected NPCs support replication that ultimately
results in increased cell death over time. Importantly, CD8þ T cells
kill NPCs pulsed with viral-peptides, and JHMV replication in
NPCs was suppressed, in part, by IFN-γ secreted from virus-spec-
iﬁc CD4þ T cells.
Results
NPCs express the MHV receptor CEACAM1a and are infected by JHMV
JHMV is a neurotropic coronavirus with relatively restricted
tropism for glial cells through recognition and binding to the receptor
carcinoembryonic antigen-cell adhesion molecule 1a (CEACAM1a)
(Hirai et al., 2010; Thorp and Gallagher, 2004). CEACAM1a expression
in mouse tissues is widespread and can be detected on the surface of
a variety of epithelial cells in the gastrointestinal, respiratory, and
reproductive tracts, as well as on small vascular endothelia and
hematopoietic cells (Hemmila et al., 2004). However, CEACAM1a
expression is not ubiquitous, and although it is known to be located
at the surface of resident cells of the CNS including glia, expression
by neural stem or progenitor cells has not been evaluated. To
determine if NPCs derived from C57BL/6 transgenic mice engineered
to express GFP (GFP-NPCs) express CEACAM1a, mRNA was isolated
from cultured NPCs and receptor expression was evaluated by PCR.
Using CEACAM1a-speciﬁc primers, PCR amplicons were detected in
NPCs, as well as mixed splenocytes from C57BL/6 mice acting as
controls (Fig. 1A), and nucleotide sequencing conﬁrmed homology
with the speciﬁed region of the gene (data not shown). Furthermore,
cell surface expression of CEACAM1a was conﬁrmed with more than
90% of NPCs expressing the receptor as determined via ﬂow cyto-
metric analysis (Fig. 1B).
We next infected Sox2þ GFP-expressing NPCs with JHMV to
assess susceptibility to infection. Infected NPC cultures were ﬁxed
72 h post-infection (p.i.) and stained with an antibody speciﬁc for
the carboxyl terminus of the JHMV nucleocapsid (N) protein and
subsequently imaged using ﬂuorescence microscopy. Compared to
non-infected NPCs that form a conﬂuent monolayer when grown
in tissue culture-treated, matrigel-coated vessels, Sox2þ NPCs
infected at a multiplicity of infection (m.o.i.) of 0.1 displayed
JHMV-speciﬁc syncytia formation by 72 h post-infection (Fig. 2A).
Correspondingly, increasing viral titers were detected when pla-
que forming unit (PFU) assays were performed on supernatants
harvested from JHMV-infected NPC cultures at 24, 48, and 72 h p.i.
(Fig. 2B). Furthermore, determination of lactate dehydrogenase
(LDH) released into the supernatants of infected cultures at
deﬁned time p.i. revealed increased NPC death over time, ranging
from 10.171.5% at 24 h p.i., increasing to 29.773.7% at 48 h p.i.,
and peaking at 35.473.6% by 72 h (Fig. 2C). As JHMV replication
has been reported to occur via CEACAM1a-dependent and inde-
pendent mechanisms (Nakagaki and Taguchi, 2005), we per-
formed a monoclonal antibody blockade to determine the role
of CEACAM1a in the spread of JHMV infection in cultured
NPCs (Fig. 2D). By 72 h p.i., signiﬁcant (po0.05) inhibition of viral
replicationwas observed in anti-CEACAM1a-treated cells (4.41037
1.4103 PFU/mL, n¼3) when compared to non-treated, JHMV-
infected NPCs (2.610575.4104 PFU/mL).
MHC class I and class II expression by NPCs in response to JHMV
infection
Under normal culture conditions, expression of MHC classes I
and II is undetectable on NPCs, yet MHC expression can be induced
by treatment with IFN-γ (Chen et al., 2011; Weinger et al., 2012).
To investigate if JHMV infection alters MHC class I and/or II
expression on NPCs, we compared surface expression levels of
these molecules on non-infected and infected cells in the absence
or presence of 100 U/mL IFN-γ. Our ﬁndings indicated r1% of
NPCs were found to be positive for MHC class I (Fig. 3A and C) or II
(Fig. 3B and C) within non-infected, non-IFN-γ-treated groups.
JHMV infection did not increase either MHC class I or II (0.770.2%
and 1.370.5%, respectively) in medium-treated NPC cultures
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Fig. 1. Cultured NPCs express CEACAM1a. (A) PCR ampliﬁcation revealed that cultured C57BL/6 NPCs express transcripts speciﬁc for the JHMV receptor CEACAM1a. A 250 bp
amplicon, speciﬁc for CEACAM1a, was ampliﬁed from cDNA generated from total RNA extracted from cultured NPCs; controls included water and splenocytes isolated from
non-infected mice. (B) Representative dot plots showing CEACAM1a expression on the cell surface of C57BL/6 splenocytes (control) and cultured NPCs.
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(Fig. 3A-C). Treatment with IFN-γ (100 U/mL) for 24 h dramatically
increased levels of MHC class I (9770.7%) on non-infected NPCs,
whereas only 32.973.7% of non-infected, IFN-γ-treated NPCs
expressed MHC class II (Fig. 3A-C). IFN-γ treatment of JHMV-
infected NPCs did not substantially increase MHC class I expres-
sion (9770.8%) in comparison to non-infected IFN-γ-treated
cultures (9770.7%; Fig. 3A and C). However, MHC class II was
detected on a signiﬁcantly (po0.05) lower fraction (24.572.6%,
n¼3) of infected, IFN-γ-treated NPCs compared to non-infected,
IFN-γ-treated NPCs (32.972.1%, n¼3) (Fig. 3C). Furthermore, MHC
class II could not be detected on the majority of JHMV-infected
NPCs as determined by dual staining for viral antigen and MHC
class II (Fig. 3D).
Control of JHMV replication in infected NPCs
CD8þ and CD4þ T cells are pivotal in controlling JHMV
replication within the infected CNS (Sussman et al., 1989;
Williamson and Stohlman, 1990). Virus-speciﬁc effector CD8þ T
cells help control replication in infected astrocytes and microglia
through cytolytic activity (Bergmann et al., 2004). In addition to
secreting IFN-γ that limits viral replication in oligodendrocytes,
CD8þ T cells carry out perforin-dependent cytolysis of astrocytes
and microglia (Bergmann et al., 2004; Williamson and Stohlman,
1990). We co-cultured virus-speciﬁc CTLs at diminishing effector-
to-target (E:T) ratios with NPCs pulsed with the immunodominant
CD8 peptide speciﬁc for JHMV spike (S) glycoprotein spanning
amino acids 510–518 (S510–518), and treated with IFN-γ to induce
MHC class I expression. Subsequently, LDH released in the super-
natants was evaluated to quantify CTL-mediated NPC lysis; RMA-S
cells, a murine lymphoma cell line that presents viral peptides to
CTLs in an MHC class I dependent manner, were used as positive
control (Debruijn et al., 1991). NPCs pulsed with S510–518 peptide
were speciﬁcally lysed by virus-speciﬁc CTLs at an E:T ratio of 10–1
(po0.05, n¼3), indicating that virus-speciﬁc CD8þ T cells are
capable of recognizing and directly killing JHMV-infected NPCs
in vitro (Fig. 4). Importantly, this cytolytic effect waned as the E:T
to target ratio declined. CD4þ T cells have both indirect and direct
antiviral roles during acute JHMV-induced encephalomyelitis,
which include inducing the effector functions of virus-speciﬁc
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Fig. 2. JHMV infection of cultured NPCs. (A) GFP-expressing NPCs were infected with JHMV (m.o.i.¼0.1) for 18 h. After a 72 h incubation, cells were ﬁxed and stained with
antibodies speciﬁc for Sox2 (red) and the JHMV nucleocapsid (N) protein (blue) and visualized by ﬂuorescence microscopy (scale bar¼100 uM). Arrows indicate Sox2þ and
JHMVþ syncytia. (B) Supernatants were harvested from MHV-infected NPC cultures 24, 48, and 72 h following infection and viral titers determined by plaque assay. (C) LDH
released by infected NPCs was detected in viral supernatants and normalized to LDH levels from non-infected NPC cultures to evaluate cell death due to MHV infection.
(D) Monoclonal CC1 antibody blockade of CEACAM1a following JHMV infection resulted in signiﬁcantly (po0.05) reduced viral titers in cultured NPCs compared to non-
treated controls by 72 h p.i. For panels (B–D), data is presented as average7SEM and represents three independent experiments.
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CTLs, along with IFN-γ secretion (Savarin et al., 2008; Stohlman
et al., 2008). To evaluate if virus-sensitized CD4þ T cells can
control replication of JHMV-infected NPCs, enriched populations of
CD4þ T cells were isolated from C57BL/6 mice immunized against
the DM variant of JHMV. Subsequently, splenocytes were isolated
from JHMV-immunized and naïve mice, and magnetically-assisted
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Fig. 3. MHC expression by NPCs in response to JHMV infection. Cultured GFP NPCs were infected with JHMV (m.o.i.¼0.1) for 18 h and subsequently replenished with media
alone or containing 100 U/mL IFN-γ. Cells were incubated for 24 h and MHC class I/II expression of non-infected and infected NPCs evaluated via ﬂow cytometry. The
frequency of NPCs expressing either MHC class I (A) or MHC class II (B) is shown in representative dot plots. (C) Quantiﬁcation of the frequency of MHC I/II expression by
infected or non-infected NPCs treated with media alone or in combination with IFN-γ. Data is presented as average7SEM and represents three independent experiments
(npo0.05). (D) Representative dot plots of MHC II-positive NPCs versus JHMV-positive NPCs.
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negative selection was performed to purify the respective T cell
populations. NPC media was conditioned with CD4þ T cell
cytokines for 48 h and then added to JHMV-infected NPCs. Super-
natants from either naïve or virus-speciﬁc CD4þ T cells sup-
pressed viral replication in NPCs at 24 and 48 h post-infection,
with the most signiﬁcant inhibitory effects observed in groups
treated with media enriched with virus-speciﬁc CD4þ T cell
cytokines (Fig. 5A). However, while the suppressive effects of
naïve T cell media appeared to wane by 72 h p.i. (4.71057
2105 PFU/mL), supernatants from NPCs treated with virus-
speciﬁc CD4þ T cell conditioned media maintained low viral titers
(6.810376.3103 PFU/mL) in comparison to non-treated con-
trols (2.610575.4104 PFU/mL; Fig. 5A). T cell derived IFN-γ is
critical in controlling JHMV replication in the CNS (Bergmann
et al., 2004; Smith et al., 1991). Furthermore, treatment with IFN-γ
speciﬁcally inhibits JHMV replication in oligodendrocyte progeni-
tors (OPCs) derived from C57BL/6 NPCs, and inhibition of IFN-γ
signaling in oligodendrocytes is associated with increased viral
loads and mortality (Parra et al., 2010; Whitman et al., 2009). We
evaluated levels of IFN-γ in naïve-versus-DM speciﬁc CD4þ T cell
conditioned media by enzyme-linked immunosorbent assay
(ELISA); absorbance values from media conditioned with DM-
CD4þ T cells were increased 60-fold when compared to naïve
T cell conditioned media (po0.0001; Fig. 5B). We subsequently
treated JHMV-infected NPCs with varying amounts of mouse
recombinant IFN-γ for 24 h and determined its effects on viral
titers. NPCs treated with 1 or 10 U/mL IFN-γ maintained high
JHMV titers (1.610576.4104 PFU/mL and 1.310577.8
104 PFU/mL, respectively) in relation to non-treated groups
(1.110576.6104 PFU/mL; Fig. 5C). However, JHMV replication
in NPCs was reduced in cultures treated with 50 or 100 U/mL IFN-
γ (4.310472104 PFU/mL and 4.110472.3104 PFU/mL,
respectively; Fig. 5C). We next performed a 72-h time course to
further probe the effects of IFN-γ (100 U/mL) on JHMV-infected
NPCs. A reduction from 2.810573.4104 PFU/mL to 9.21047
4.9104 PFU/mL was observed in IFN-γ-treated cultures by 48 h
post-treatment when compared to non-treated groups (po0.05,
n¼3), and JHMV levels were reduced to 2.310473.3103 in
IFN-γ treated cultures, versus 5.210571.6105 in non-treated
cultures, by 72 h post-treatment (po0.05) (Fig. 5D). We previously
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Fig. 5. Virus-speciﬁc CD4þ T cell enriched medium reduces viral titers via IFN-γ. (A) Media enriched with cytokines from naïve or CD4þ T cells signiﬁcantly (po0.01 and
po0.001, respectively) reduced viral titers in JHMV-infected NPCs at deﬁned time p.i. compared to non-conditioned media. (B) Enzyme-linked immunosorbent assay for
IFN-γ in naïve-versus-DM-speciﬁc CD4þ T cell supernatants. Absorbance values at 490 nmwere normalized to media alone and expressed as fold changes (DM absorbance/
naïve absorbance). For statistical analysis, background-subtracted absorbance values were used (nnnnpo0.0001). (C) High doses of IFN-γ suppress JHMV replication in NPCs,
and (D) treatment with 100 U/mL IFN-γ signiﬁcantly inhibits virus replication at 72 h p.t. (E) Monoclonal antibody blockade of IFN-γ receptor abrogated the virus-
suppressive effects of DM CD4þ T cell conditioned media. For all panels, data is presented as average7SEM and represents three independent experiments (npr0.05,
nnpr0.01, and nnnpr0.001).
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showed that multiple pro-inﬂammatory cytokines secreted by DM-
speciﬁc T cells have synergistic effects with IFN-γ (Weinger et al.,
2012). To conﬁrm the role of IFN-γ as the major cytokine contribut-
ing to suppression of JHMV replication in infected NPC cultures,
monoclonal antibody blockade against the IFN-γ receptor was
performed on NPCs before and during treatment with virus-
speciﬁc CD4þ T cell enriched media. As expected, by 48 h p.t.
JHMV levels were signiﬁcantly (po0.01) reduced in conditioned
media treated cultures compared to NPCs grown in non-conditioned
media (1.310571.8104 and 3.110572.4104 PFU/mL, respe-
ctively; Fig. 5E). However, treatment with anti-IFN-γ receptor
resulted in higher (po0.05) viral titers (5.410571.4105) com-
pared to CD4þ T cell media treated cultures, thereby conﬁrming the
pivotal role of IFN-γ in CD4þ T cell mediated suppression of JHMV in
NPCs. We have previously shown that IFN-γ treatment of JHMV-
infected OPCs increases IFN-α/β secretion, and treatment with IFN-β
suppresses JHMV replication (Whitman et al., 2009). Type I inter-
feron (IFN-β) levels in JHMV-infected, IFN-γ treated NPC super-
natants were assessed by ELISA and IFN-β was not detected above
background levels (data not shown).
Effects of IFN-γ treatment on CEACAM1a and JHMV structural
proteins
We evaluated the expression of the JHMV receptor CEACAM1a
on NPCs following treatment with 100 U/mL IFN-γ and did not
observe a change in the frequency of CECAM1aþ NPCs between
treated and non-treated groups at 24 h p.t. (Fig. 6A and B). However,
by 48 h p.t. the frequency of CEACAM1aþ NPCs decreased from
86.171.8% in non-treated NPCs to 62.472.5% in IFN-γ treated
cultures, and by 72 h p.t. 61.973.5% IFN-γ treated NPCs expressed
CEACAM1a (compared to 73.370.5%), indicating that IFN-γ dam-
pens JHMV receptor expression by NPCs. The JHMV membrane
(M) glycoprotein is critical in virus assembly (Matthews et al., 2002).
To determine if M transcripts were decreased following IFN-γ
treatment, gene-speciﬁc quantitative PCR (qPCR) was performed on
total RNA extracts from JHMV-infected NPCs and M transcript levels
were normalized to β-actin. M expression was signiﬁcantly reduced
in IFN-γ treated NPCs compared to non-treated NPCs at 48 and 72 h
p.t. (po0.05; Fig. 6C). These ﬁndings suggest that the IFN-γ-
induced inhibitory effect on JHMV replication within NPCs is related
to both muted expression of CEACAM1a and inhibition of viral RNA
synthesis.
Discussion
This study demonstrates that NPCs derived from the brains of
post-natal C57BL/6-GFP mice express the JHMV receptor, CEA-
CAM1a, and support viral replication following CEACAM1a-
dependent infection. Additionally, JHMV infection of cultured
NPCs induces cytopathic effects over time as evidenced by syncytia
formation and elevated LDH levels. Within the context of JHMV
infection of the CNS, these ﬁndings demonstrate that resident
NPCs present within deﬁned anatomical niches may be susceptible
to viral infection. Moreover, we have previously shown that
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intraspinal transplantation of NPCs into mice persistently infected
with JHMV results in clinical recovery associated with remyelina-
tion (Carbajal et al., 2010; Totoiu et al., 2004). Data presented
within this report argues that transplanted NPCs may be suscep-
tible to JHMV infection, a ﬁnding that highlights important clinical
implications for emerging therapies utilizing NPCs to treat human
neurologic disease as engrafted cells may be susceptible to infec-
tion by persistent neurotropic viruses.
JHMV infection has previously been shown to inhibit constitu-
tive expression of MHC class I in mouse primary astrocyte cultures
and to block IFN-γ-induced MHC class II expression on murine
cerebral endothelial cells (Correale et al., 1995; Joseph et al., 1991).
Here, we show that JHMV does not signiﬁcantly affect MHC class I
or II expression following infection of cultured NPCs in the absence
of IFN-γ. However, IFN-γ-induced expression of MHC class II was
reduced following JHMV infection. MHC expression plays an impor-
tant role in immune surveillance during viral infection, and control
of JHMV replication within the CNS requires antigen recognition by
MHC class I and MHC class II restricted CD8þ and CD4þ T cells
(Bergmann et al., 2004; Sussman et al., 1989; Williamson and
Stohlman, 1990). Impaired expression of MHC class II following
IFN-γ-treatment of infected NPCs may be a mechanism employed to
subvert detection by inﬁltrating virus-speciﬁc CD4þ T cells. None-
theless, conditioned medium from virus-speciﬁc CD4þ T cells was
able to suppress JHMV replication within NPCs, likely due to the
effects of IFN-γ. Supporting this notion, treatment of infected NPCs
with recombinant mouse IFN-γ had a dose-dependent inhibitory
effect on virus replication, and blocking IFN-γ receptor abrogated
the observed suppressive effects. IFN-γ treatment resulted in fewer
CEACAM1a-expressing NPCs with a concomitant decrease in JHMV
membrane glycoprotein transcripts, suggestive of viral entry inhibi-
tion and reduced virion assembly. We also observed that NPCs
pulsed with the CD8-speciﬁc viral peptide S510–518 were detected
and killed by virus-speciﬁc CD8þ T cells, indicating that virally-
infected NPCs may be targeted for lysis by CTLs inﬁltrating into the
CNS in response to infection. Collectively, our ﬁndings argue that T
cells are important for controlling viral replication within NPCs
through both cytolytic activity and IFN-γ secretion.
Lineage fate mapping of neural stem/precursor cells residing
within the subventricular zone of lateral ventricles and subgranular
zone of the hippocampus demonstrates the ability of these cells to
differentiate into neurons and glia throughout development (Doetsch,
2003; Gage, 2000). Furthermore, endogenous NPCs have been shown
to proliferate, migrate, and differentiate in response to acute CNS
inﬂammatory events, such as with spinal cord injury, stroke, and
experimental models of chronic inﬂammatory demyelinating disor-
ders (Picard-Riera et al., 2002; Yagita et al., 2001; Zhang et al., 2004).
Though viewed as a glial tropic virus, this study highlights the
potential for NPCs to serve as a reservoir for JHMV infection and
replication. CTL-mediated lysis of JHMV-infected NPCs may be detri-
mental to NPC-mediated repair during CNS inﬂammation, and a loss
of NPCs destined to become oligodendrocytes could contribute to
limited remyelination observed in the JHMV-infected CNS. Addition-
ally, our ﬁndings have clinical relevance, as NPCs are currently being
employed in clinical trials for spinal cord injury as well as for treating
the Pelizaeus–Merzbacher disease, a genetic disorder that affects the
growth of the myelin sheath (Gupta et al., 2012; Mayor, 2010).
As NPCs used for clinical trials are unlikely to be “self-derived”, they
would be subject to immune recognition and potential destruction by
both innate and adaptive immune responses, necessitating long-term
immune suppression to prevent graft rejection (Chen et al., 2011;
Swijnenburg et al., 2008; Weinger et al., 2012). Several classes of
immunosuppressive drugs used during transplantation, including
calcineurin inhibitors i.e. cyclosporine and FK506, inhibit the activa-
tion and/or proliferation of T cells. Such immunosuppressive drugs
would foster an environment whereby opportunistic infection or
reactivation of latent virus might occur. This raises the possibility that
transplanted NPCs may be subject to infection, and in the absence of
adequate immune surveillance of the CNS, could lead to damage/
death of engrafted cells. With this in mind, careful consideration
should be given to potential viral infection when contemplating NPC
grafting for treating neurological disease.
Materials and methods
Virus
The JHM strain of mouse hepatitis virus (J2.2v-1) was added to
NPC cultures at a multiplicity of infection (MOI) of 0.1 PFU/cell.
Virus was allowed to absorb overnight (16–18 h) before media
were replaced. Supernatants of infected cultures were collected at
deﬁned time p.i. and viral titers were determined using the DBT
astrocytoma cell line as previously described (Hirano et al., 1976).
Neural precursor cell culture and reagents
NPCs derived from the striatum of post-natal day 1 transgenic
C57BL/6 mice expressing enhanced green ﬂuorescent protein
(GFP) were cultured as previously described (Carbajal et al.,
2010). NPC media consisted of DMEM/F12 with Glutamax (Gibco),
N2 supplement (1X, Gibco), ciproﬂoxacin hydrochloride (100 μg/
mL, Cellgro), gentamicin (50 μg/mL, Sigma-Aldrich), Fungizone
(2.5 μg/mL, Gibco), penicillin/streptomycin (1000 U/mL, Gibco),
and human epidermal growth factor (20 ng/mL, Sigma-Aldrich).
Recombinant mouse IFN-γ was purchased from Cell Sciences. For
studies involving blockade of CEACAM-1a, NPCs were infected
overnight and monoclonal antibody CC1 (eBiosciences) was sub-
sequently added at a concentration of 1 μg/mL. Media were
harvested 72 h p.i. and plaque assay performed to determine viral
titers. Experimental blockade of IFN-γ receptor was performed
using JHMV-infected NPCs incubated with 250 nM (ﬁnal) anti-
mouse CD119 (IFN gamma receptor 1; eBiosciences) or 250 nM
puriﬁed rabbit IgG (control; BD Pharmigen) for 1 h before media
were replaced with non-conditioned or CD4þ T cell conditioned
media þ/ anti-mouse CD119 or rabbit IgG. Supernatants were
harvested 48 h post-treatment and viral titers determined.
Flow cytometric analysis
Cultured NPCs were dissociated using 0.05% trypsin–EDTA and
suspended in PBS containing 0.5% BSA and 2 mM EDTA (Invitro-
gen). Cells were subsequently treated with blocking antibody
(puriﬁed rat IgG2b anti-mouse CD16/CD32 monoclonal antibody,
1:200; BD Biosciences) for 20 min at 4 1C before being incubated
with antibodies speciﬁc for CEACAM1a (APC-conjugated, 0.06 μg/
test, eBioscience), MHC class I (PE-conjugated, 1:200, eBioscience),
or MHC class II (PE-conjugated, 1:200, BD Biosciences), for
20–30 min. In experiments where FACS analysis of JHMV was
performed, NPCs were ﬁxed with 4% paraformaldhyde for 15 min
before being permeabilized using BD Perm/Wash buffer (BD
Biosciences). The anti-JHMV mAb J.3.3 speciﬁc for the carboxyl
terminus of the viral nucleocapsid (N) protein was conjugated to
Alexa Fluor 647 using the APEX labeling system (Life Technologies)
and used at a ﬁnal concentration of 1.5 ng/mL. Detection of
ﬂuorescence was performed using a LSR II ﬂow cytometer (BD
Biosciences) and analysis of FACS data was performed with FlowJo
software (Tree Star).
W.C. Plaisted et al. / Virology 449 (2014) 235–243 241
RNA isolation, reverse transcription, and polymerase chain reaction
Total RNA was isolated from C57BL/6 splenocytes and NPCs using
TRIzol reagent (Invitrogen) and puriﬁed by phenol–chloroform
extraction. cDNA was reverse transcribed from RNA according to
manufacturer's instructions using the SuperScript III First-Strand
Synthesis system (Invitrogen) and random hexamers. Standard
PCR for CEACAM1a expression was performed with an Eppendorf
Mastercycler using the Platinum Taq DNA polymerase kit (Invitro-
gen) and the following primers purchased from Integrated DNA
Technologies: TTCCCTGGGGAGGACTACTG (forward primer) and
TGTATGCTTGCC CCGTGAAAT (reverse primer). Gene products
were run alongside a 1 kb Plus DNA ladder (Invitrogen) on a 1%
agarose gel containing ethidium bromide before being imaged
using the Bio-Rad GelDoc system. For quantitative RT-PCR experi-
ments, primers speciﬁc for the JHMV membrane protein (forward:
CGAGCCGTAGCATGTTTATCTA; reverse: CGCATACACGCAATTGAA-
CATA) were designed using PrimerQuest software (Integrated
DNA Technologies, Inc.). SYBR Green Real-Time PCR Master Mix
(Life Technologies) was used according to manufacturer's speciﬁ-
cations and RT-PCR was performed using the Applied Biosystem
ViiA 7 Real-Time PCR System. Ct values of M protein transcripts
were normalized to β-actin Ct values (forward: GGCCCAGAGCAA-
GAGAGGTATCC; reverse: ACGCACGATTTCCCTCTCAGC) and com-
pared using the ΔΔCt method.
Immunoﬂuorescence
To evaluate JHMV infection of cultured NPCs, cells were
dissociated and plated on slides or cover slips coated with reduced
growth factor Matrigel (BD Biosciences). NPCs were infected with
JHMV overnight and ﬁxed 72 h p.i. with 4% paraformaldehyde for
10 min at room temperature. Immunoﬂuorescence staining was
performed as previously described (Whitman et al., 2009) using
the anti-JHMV mAb J.3.3 (1:20 dilution) speciﬁc for the carboxyl
terminus of the viral nucleocapsid (N) protein and the Alexa Fluor
405 goat anti-mouse IgG1 secondary antibody (Life Technologies),
as well as rabbit monoclonal anti-Sox2 (Epitomics) and Alexa Fluor
568 goat anti-rabbit IgG1 secondary antibody (Life Technologies).
Slides were imaged using a Nikon Eclipse Ti inverted microscope.
JHMV-induced cell death assay
NPC death due to JHMV infection was evaluated at 24, 48, and
72 h p.i. by measuring lactate dehydrogenase released by lysed
cells according to manufacturer's recommendations using the
CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega). Brieﬂy,
spontaneous and virus-induced LDH levels were determined using
the following formula: % Lysis¼(Experimental LDH release)/(Max-
imum LDH release). LDH levels from JHMV-infected cultures were
then normalized to spontaneously released LDH and expressed as
cell death due to infection (%).
CD4þ T cell isolation for NPC media conditioning
C57BL/6 mice were infected with an i.p. injection of 2.5105 PFU
of a demyelinating (DM) variant of JHMV. On day 8 p.i., CD4þ T cells
were isolated from spleens by negative selection according to
manufacturer's speciﬁcations using the EasySep Mouse CD4þ T cell
Isolation kit (Stemcell Technologies). Brieﬂy, red blood cell depleted
splenocytes were suspended at a concentration of 1108 cells/mL in
PBSþ2% FBS with 1 mM EDTA. Normal rat serum was added at the
appropriate concentration and cells were incubated with a cocktail
containing a combination of biotinylated monoclonal antibodies
directed against CD8a, CD11b, CD11c, CD19, CD45R/B220, CD49b,
TCRγ/δ and TER119, for 10 min. Subsequently, a suspension of
streptavidin-coated magnetic particles in PBS was added and incu-
bated with the cells for 2.5 min; buffer was added to the appropriate
volume, and cells were incubated in the EasySep Magnet for 2.5 min
to foster binding of magnetically-labeled unwanted cells to the tube
walls before CD4þ T cells were poured off. To generate CD4þ T cell
conditioned NPC media, the magnetically-labeled fraction following
depletion of total T cells was collected using the EasySep Mouse T
Cell Isolation kit (Stemcell technologies). This enriched fraction was
treated with 50 μg/mL mitomycin-C (AG Scientiﬁc), and 35106
cells were co-cultured with 35106 CD4þ T cells in 10 mL NPC
media containing 5 μm CD4-speciﬁc membrane (M) glycoprotein
spanning amino acid residues 133–147 (M133–147, Bio-Synthesis) for
48 h. CD4þ T cell conditioned media were administered to JHMV-
infected NPCs and supernatants were harvested 24, 48, and 72 h p.i.
for determination of viral titers. Levels of IFN-γ in CD4þ T cell
conditioned media were determined by ELISA using the Mouse IFN-γ
DuoSet according to manufacturer's recommendations (R&D Sys-
tems). Interferon-β levels in JHMV-infected NPC cultures were
evaluated using the VeriKine Mouse Interferon Beta ELISA kit (PBL
Assay Science). The animal protocols and procedures used for these
studies were reviewed and approved by the Institutional Animal Care
and Use Committee of the University of California, Irvine.
CD8þ T cell cytotoxicity assay
NPCs were seeded at a density of 20,000 cells/well in a ﬂat-
bottom 96-well format tissue culture plate (Corning Life Sciences)
and pulsed overnight with 5 μM of the immunodominant CD8
peptide speciﬁc for MHV spike (S) glycoprotein spanning amino
acids 510–518 (S510–518, Bio-Synthesis). NPCs were simulta-
neously treated overnight with 100 U/mL IFN-γ to induce MHC
class I expression for the presentation of S510–518. CD8þ T cells
isolated from DM-infected C57BL/6 mouse splenocytes (as men-
tioned for CD4þ T cells) using the EasySep Mouse CD8þ T cell
Isolation kit (Stemcell Technologies) were then plated with NPCs
at effector-to-target (E:T) ratios ranging from 10:1 to 0.31:1. Co-
cultures were incubated for 4 h at 37 1C in 5% CO2 at a ﬁnal volume
of 200 μL/well. The amounts of lactate dehydrogenase released
from lysed cells were determined using a CytoTox 96 Non-
Radioactive Cytotoxicity Assay (Promega). The percentage of CTL-
mediated lysis was determined as speciﬁed by the manufacturer's
protocols. RMA-S cells pulsed overnight with 50 μM S510–518
were used as a positive control for cell lysis.
Statistical analysis
Statistical analysis was carried out using Student's t test, one-
way ANOVA, or repeated measures ANOVA and pr0.05 was
considered signiﬁcant.
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